Status unknownNot a drug-phase studyRelapsing MSNCT05779449

We could not find results for this trial

I know where the results are

What it found

No result found

We found no results in the registry or in papers.

What was tested

Treatment tested

  • Prebiotics and Probiotics supplementation
  • peripheral blood withdrawal
  • Transcranial Magnetic Stimulation (TMS)

Placebo or sham

  • Placebo supplementation

What it measured

Main measures

  • Changes in gut microbiota diversity or composition

    T0 vs T12 (months), Pre-Pro versus Placebo groups

  • Changes in microbiota metabolites - indican

    T0 vs T12 (months), Pre-Pro versus Placebo groups

  • Changes in microbiota metabolites - skatole

    T0 vs T12 (months), Pre-Pro versus Placebo groups

  • Changes in serum glutamate

    T0 vs T12 (months), Pre-Pro versus Placebo groups

  • Changes in serum synaptotoxic miRNAs

    T0 vs T12 (months), Pre-Pro versus Placebo groups

  • Changes in plasma inflammatory molecules

    T0 vs T12 (months), Pre-Pro versus Placebo groups

  • Changes in immunophenotype

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Immune response
  • Changes in T cell metabolic asset

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Immune response

Other measures (17)

  • Changes in neurophysiological response

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Myelin repairNerve conduction tests
  • Changes in clinical disability

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Disability progression
  • Changes in lower extremity function

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Disability progressionWalking and mobility
  • Changes in upper extremity function

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Disability progressionArm and hand function
  • Changes in quality of life

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Thinking and memoryFatigueBladder, bowel and sexual functionQuality of life (reported by participants)
  • Assessment of mild to moderate dysfunctions

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Disability progressionThinking and memory
  • Changes in global cognitive disability

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Thinking and memory
  • Assessment of attention and information processing speed

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Thinking and memory
  • Changes in phonemic verbal fluency

    T0 vs T12 (months), Pre-Pro versus Placebo groups

  • Changes in verbal memory performance

    T0 vs T12 (months), Pre-Pro versus Placebo groups

    Thinking and memory

Who could take part

Relapsing MS · 18 to 65

Inclusion Criteria: * RRMS diagnosis, as Polman et al 2011. Ann Neurol. PMID: 21387374 * Age \<= 18 and => 65 years * EDSS score \<= 7 * Disease duration \< 10 years * On DMF or Ocrelizumab treatment from at least 3 months * No corticosteroid administration in the previous month * Ability to provide written informed consent. Exclusion Criteria: * Adverse effects to gadolinium * Blood count basal alteration * Pregnant or lactating women * Vegetarians or vegans * Taking antibiotics, any product or supplement containing probiotics, Omega 3 or other antioxidant supplements within 30 days prior to inclusion * History of food allergies or food intolerance * Clinically significant medical condition other than MS, (latent infections, other autoimmune disease) * Diagnosis of past eating disorders (anorexia, bulimia, or binge eating) or relevant psychiatric disorders.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

Inflammatory synaptopathy is a prominent pathogenic process in multiple sclerosis (MS) induced by imbalanced immune system homeostasis. Its persistence causes excitotoxic neuronal damage, leading to motor and cognitive deficits. Although many advances have been made in MS treatment, the development of effective strategies for managing disease progression driven by excitotoxic synaptic dysfunctions is of great significance. Gut dysbiosis is commonly associated with both MS and obesity and high-fat diet (HFD) can exacerbate disease by acting on gut microbiota. Since gut microbiota can shape the immune response and brain functions, we propose to target gut dysbiosis by dietary supplementation of prebiotics and probiotics (Pre-Pro) to treat synaptopathy in both human and experimental model of MS, even when exacerbated by HFD. Overall, this project aims at unveiling the anti-inflammatory and neuroprotective pathways activated by Pre-Pro supplementation to modulate the immune-synaptic axis.

Papers

Loading reviews and guidelines…

Related trials

History

    1. Started

      Jul 2023

    2. Main results due

      Nov 2024

    3. Finished

      May 2026

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error